Development of ligustrazine-loaded lipid emulsion: Formulation optimization, characterization and biodistribution

Wei, Liang; Marasini, Nirmal; Li, Gao; Yong, Chul Soon; Kim, Jong Oh; Quan, Qi-Zhe

doi:10.1016/j.ijpharm.2012.08.027

Cited by 23 publications

(15 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…by Wei et al (2012). Briefly, ten milliliter samples of blood were withdrawn from each rabbit and transferred into heparin-treated tubes.…”

Section: In Vitro Hemolytic Studiesmentioning

confidence: 99%

“…However, it should be considered that many factors could 500 influence the in vivo hemolytic potential such as the drug concentration of the formulation, the rapidity of injection as well as the contact duration with the cell membrane (Wei et al, 2012). …”

Section: In Vitro Hemolytic Studiesmentioning

confidence: 99%

“…The incorporation of albumin would augment these effects by minimizing the possible association of LP6 NPs with serum proteins and/or the rapid clearance of the reticuloendothelial system (Xu et al, 2010;Zhou et al, 2013). In this conceptual framework, the 560 reduced hepatic uptake might have enabled CHL to achieve higher levels in the blood for a prolonged period; compared to CHL solution (Wei et al, 2012). …”

Section: In Vivo Absorption Studies In Ratsmentioning

confidence: 99%

See 2 more Smart Citations

Long-circulating lipoprotein-mimic nanoparticles for smart intravenous delivery of a practically-insoluble antineoplastic drug: Development, preliminary safety evaluations and preclinical pharmacokinetic studies

Tadros

Al-mahallawi

2015

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…by Wei et al (2012). Briefly, ten milliliter samples of blood were withdrawn from each rabbit and transferred into heparin-treated tubes.…”

Section: In Vitro Hemolytic Studiesmentioning

confidence: 99%

Section: In Vitro Hemolytic Studiesmentioning

confidence: 99%

Section: In Vivo Absorption Studies In Ratsmentioning

confidence: 99%

See 1 more Smart Citation

Long-circulating lipoprotein-mimic nanoparticles for smart intravenous delivery of a practically-insoluble antineoplastic drug: Development, preliminary safety evaluations and preclinical pharmacokinetic studies

Tadros

Al-mahallawi

2015

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…Depending upon the solubility, antigens are either dispersed into aqueous or oil phases to form droplets of w/o or o/w emulsions. Thus, direct contact of antigens with gastric fluids is avoided, which increases gastric stability [64]. Additionally, the presence of surfactant(s) in the emulsion system provides better stability against premature leakage of antigens in the GI fluid, which further enhances their permeation across the luminal wall [60].…”

Section: Nanoemulsionmentioning

confidence: 99%

Oral delivery of nanoparticle-based vaccines

Marasini

Skwarczynski

Tóth

2014

Expert Review of Vaccines

Self Cite

134

100

View full text Add to dashboard Cite

Most infectious diseases are caused by pathogenic infiltrations from the mucosal tract. Therefore, vaccines delivered to the mucosal tissues can mimic natural infections and provide protection at the first site of infection. Thus, mucosal, especially, oral delivery is becoming the most preferred mode of vaccination. However, oral vaccines have to overcome several barriers such as the extremely low pH of the stomach, the presence of proteolytic enzymes and bile salts as well as low permeability in the intestine. Several formulations based on nanoparticle strategies are currently being explored to prepare stable oral vaccine formulations. This review briefly discusses several molecular mechanisms involved in intestinal immune cell activation and various aspects of oral nanoparticle-based vaccine design that should be considered for improved mucosal and systemic immune responses.

show abstract

“…The Higuchi equation was best fitted for DOX release from DOX/FA-PEG-P(HB-HO) NPs as indicated by a higher correlation coefficient (R 2 ¼ 0.9938) compared with zero-order (R 2 ¼ 0.8263) and first-order models (R 2 ¼ 0.9780) ( Table 3). DOX/FA-PEG-P(HB-HO) NPs showed a desirable sustained release property, suggesting that the drug incorporated into the nanoparticles is retained for a certain amount of time, which allows for slow release into the medium (Wei et al, 2012). Therefore, DOX in the nanoparticles could be released in a sustained manner as shown in Figure 3.…”

Section: Physico-chemical Characterizations Of Dox/fa-peg-p(hb-ho) Npsmentioning

confidence: 99%

Folate-decorated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting delivery: optimization andin vivoantitumor activity

Zhang

2015

Drug Delivery

View full text Add to dashboard Cite

Context: Doxorubicin (DOX)-loaded folate-targeted poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) [P(HB-HO)] nanoparticles [DOX/FA-PEG-P(HB-HO) NPs] have potential application in clinical treatments for cervical cancer due to specific affinity of folate and folate receptor in HeLa cells. Objective: The aim of this study was to develop an optimized formulation for DOX/FA-PEG-P(HB-HO) NPs, and investigate the targeting and efficacies of the nanoparticles. Materials and methods: DOX/FA-PEG-P(HB-HO) NPs were prepared by W 1 /O/W 2 solvent extraction/evaporation method, and an orthogonal experimental design [L 9 ( 3 4 )] was applied to establish the optimum conditions. The physico-chemical characteristics, microscopic observation and in vivo antitumor study of the nanoparticles were evaluated. Results: The optimum formulation was obtained with DOX 10% (w/v), FA-PEG-P(HB-HO) 6.5% (w/v), PVA 3%(w/v) and oil phase/internal water phase volume ratio of 3/1. The size distribution, drug loading and encapsulation efficiency of the optimized nanoparticles were 150-350 nm, 29.6 ± 2.9% and 83.5 ± 5.7%, respectively. In vitro release study demonstrated that 80% of the drug could release from the nanoparticles within 11 days. Furthermore, in vitro microscopic observation and in vivo antitumor study showed that DOX/FA-PEG-P(HB-HO) NPs could inhibit HeLa cells effectively, and the tumor inhibition rate (TIR) in vivo was 76.91%. Discussion and conclusions: DOX/FA-PEG-P(HB-HO) NPs have been successfully developed and optimized. In vitro drug release study suggested a sustained release profile. Moreover, DOX/FA-PEG-P(HB-HO) NPs could effectively inhibit HeLa cells with satisfying targeting, and reduce side effects and toxicity to normal tissues. DOX/FA-PEG-P(HB-HO) NPs were superior in terms of inhibiting HeLa tumor over non-targeted formulations therapy. KeywordsDoxorubicin, folate-targeted nanoparticles, in vivo antitumor activity, orthogonal design, poly(3-hydroxybutyrateco-3-hydroxyoctanoate)History

show abstract

Development of ligustrazine-loaded lipid emulsion: Formulation optimization, characterization and biodistribution

Cited by 23 publications

References 40 publications

Long-circulating lipoprotein-mimic nanoparticles for smart intravenous delivery of a practically-insoluble antineoplastic drug: Development, preliminary safety evaluations and preclinical pharmacokinetic studies

Long-circulating lipoprotein-mimic nanoparticles for smart intravenous delivery of a practically-insoluble antineoplastic drug: Development, preliminary safety evaluations and preclinical pharmacokinetic studies

Oral delivery of nanoparticle-based vaccines

Folate-decorated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting delivery: optimization andin vivoantitumor activity

Contact Info

Product

Resources

About